ARTICLE | Company News

Amgen regains denosumab rights from GSK

April 4, 2014 12:34 AM UTC

Amgen Inc. (NASDAQ:AMGN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) mutually agreed to end part of a 2009 deal under which GSK had rights to co-commercialize Amgen's Prolia denosumab for postmenopausal osteoporosis in the EU, Switzerland, Norway, Russia, Mexico and New Zealand. Amgen will pay GSK $275 million in cash in an undisclosed upfront payment and milestones. According to Amgen, Prolia had 2013 sales of about $200 million for osteoporosis in the countries.

GSK retains rights to co-commercialize Prolia in Australia under the 2009 deal. Under a separate 2009 deal, the pharma is commercializing denosumab for all indications in about 40 other countries where Amgen did not have a commercial presence at the time the deal was signed, including China, Brazil, India and South Korea. Denosumab is approved as Xgeva and Prolia for cancer indications, including to prevent skeletal related events (SREs) in adults with bone metastases from solid tumors. ...